Here’s a revised version of the text, incorporating verification and adhering to the provided instructions:
Earlier this month, Medtronic [reported](https://www.medicaldevice-network.com/news/medtronic-three-milestones-minimed-780g/) three milestones in the US, expanding access to its MiniMed 780G insulin delivery system for individuals with type 1 diabetes (T1D) and insulin-requiring type 2 diabetes (T2D). Thes advancements include expanded age indications, increased coverage with major payers, and the availability of the system through durable medical equipment (DME) pharmacies.
Specifically, the MiniMed 780G system is now approved for use in children as young as two years old, down from a previous age limit of six [Medtronic News Release](https://investors.medtronic.com/news-releases/news-release-details/medtronic-announces-us-milestones-expanding-access-minimed-780g). Furthermore, Medtronic has secured broader insurance coverage for the system, making it more accessible to a wider patient population. the system is now available through a network of DME pharmacies, streamlining the process for patients to obtain the device [Medical Device and Diagnostics Industry](https://www.mddionline.com/regulatory/medtronic-expands-access-minimed-780g-system).
